Arthur F. Ryan has filed 93 Form 4 transactions, all in Regeneron Pharmaceuticals (REGN), and every one of them is an open-market sale. The total sell value across his filings is $791,650.68. There are no purchases, no option exercises, and no grants in the record. The pattern is one-directional: he has sold REGN shares repeatedly and has not acquired any.
The recent activity is concentrated in monthly clusters. On March 2, 2026, Ryan filed seven sales totaling roughly $47,113. On April 1, he filed eight sales worth about $71,530. The May 1 cluster is the largest by count, with ten sales adding up to roughly $55,794. The most recent trade, dated July 2, 2026, is a single sale of $130,030, which is the largest individual transaction in the recent set. The dollar values within each cluster vary widely, from a $712 sale on May 1 to the $130,030 July trade.
The absence of any buy-side activity, combined with the steady cadence of sales, shows a consistent seller bias. The transactions are all coded as "S," meaning open-market sales, not automatic tax withholdings or gifts. Ryan has not diversified across companies; REGN is the only ticker in his filing history. The recent direction is unchanged: he sold in March, April, May, and July, with no indication of a pause.
AI-assisted summary